YOUR BUSINESS AUTHORITY
Springfield, MO
The U.S. Food and Drug Administration on Monday cleared an experimental drug from Eli Lilly for people with mild or moderate COVID-19 symptoms not requiring hospitalization.
The antibody drug, called bamlanivimab, is similar to a treatment President Donald Trump received after contracting the virus last month. The government previously reached an agreement to buy and supply much of the early production of Lilly’s drug.
Officials say bamlanivimab requires additional testing to establish its safety and effectiveness.
Read more from The Associated Press.
Organizers hope to bolster client traffic to center city businesses.
AI expert gives advice at SBJ's People You Need to Know
European-style Christmas market to make debut in Branson next week
Big Cedar Lodge golf courses place on Golfweek list
Original, historic Pipkin building up for sale
Pizza Hut co-founder Dan Carney dies
Annual downtown holiday events combine for Nov. 21 celebration